Evaluation of the clinical efficacy of asenapine in schizophrenia

Dosing Frequency and Adherence to Antipsychotic Medications

(2015) Paul N. Pfeiffer et al.   PSYCHIATRIC SERVICES

Special Section on Implications of CATIE: Lessons to Take Home From CATIE

(2014) William T. Carpenter et al.   PSYCHIATRIC SERVICES

Iloperidone for the Treatment of Schizophrenia

(2010) Jehan Marino et al.   ANNALS OF PHARMACOTHERAPY

Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia

(2010) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Citation Bias in Reported Smoking Prevalence in People with Schizophrenia

(2009) Simon Chapman et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Asenapine versus olanzapine in acute mania: a double-blind extension study

(2009) Roger S McIntyre et al.   BIPOLAR DISORDERS

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

(2009) Roger S McIntyre et al.   BIPOLAR DISORDERS

Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia

(2009) LE Friberg et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Asenapine

(2009) Juliane Weber et al.   CNS DRUGS

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

(2009) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors

(2009) Yong Kee Choi et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Exposure-Response Analysis in Patients With Schizophrenia to Assess the Effect of Asenapine on QTc Prolongation

(2009) Sunny Chapel et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Risperidone Long-Acting Injection

(2009) David M. Taylor et al.   JOURNAL OF CLINICAL PSYCHIATRY

Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia

(2009) Jared W. Young et al.   PHARMACOLOGY & THERAPEUTICS

Asenapine effects in animal models of psychosis and cognitive function

(2009) Hugh M. Marston et al.   PSYCHOPHARMACOLOGY

Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain

(2009) Frank I. Tarazi et al.   SYNAPSE

The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity

(2008) Keith H. Nuechterlein et al.   AMERICAN JOURNAL OF PSYCHIATRY

Upcoming Agents for the Treatment of Schizophrenia

(2008) Delia Bishara et al.   DRUGS

Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: Relevance to animal models of antipsychotic drugs

(2008) Tao Sun et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Long-acting risperidone improves negative symptoms in stable psychotic patients

(2008) VA Curtis et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

(2008) M. Shahid et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions

(2008) David S. Tait et al.   PSYCHOPHARMACOLOGY

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study

(2008) Daniel E. Casey et al.   PSYCHOPHARMACOLOGY

Realistic expectations of prepulse inhibition in translational models for schizophrenia research

(2008) Neal R. Swerdlow et al.   PSYCHOPHARMACOLOGY

Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment

(2008) J. Parks et al.   SCHIZOPHRENIA BULLETIN

CNTRICS Final Task Selection: Control of Attention

(2008) K. H. Nuechterlein et al.   SCHIZOPHRENIA BULLETIN

Selecting Paradigms From Cognitive Neuroscience for Translation into Use in Clinical Trials: Proceedings of the Third CNTRICS Meeting

(2008) D. M. Barch et al.   SCHIZOPHRENIA BULLETIN